AT1 receptor blockade for the prevention of cardiovascular events after myocardial infarction

References

• American Heart Association. Heart Disease and Stroke Statistics — 2004 Update. American Heart Association, TX, USA (2004).
   Google Scholar
• Timmermans PB, Chiu AT, Herblin WF et al. Angiotensin II-receptor subtypes. Am. Hypertens. 5,406–410 (1992).
   PubMed Web of Science ®Google Scholar
• Unger T, Chung 0, Csikos T et al. Angiotensin receptors. J. Hypertens. 14\(Suppl. 5), S95—S103 (1996).
   Google Scholar
• Harada K, Sugaya T, Murakami K et al. Angiotensin II Type 1A receptor knockout mice display less left ventricular remodeling and improved survival after myocardial infarction. Circulation 100 (20), 2093–2099 (1999).
   PubMed Web of Science ®Google Scholar
• Dzau VJ, Sasamura H, Hem L. Heterogeneity of angiotensin synthetic pathways and receptor subtypes: physiological and pharmacological implications. J. Hypertens. 11\(Suppl. 3), S13—S18 (1993).
   Google Scholar
• •Nice review paper on angiotensin II receptor subtypes and blockers.
   Google Scholar
• Burnier M. Angiotensin II Type 1 receptor blockers Circulation 103,904–912 (2001).
   PubMed Web of Science ®Google Scholar
• Janiak P, Pillon A, Prost JF et al Role of angiotensin subtype 2-receptor in neointima formation after vascular surgery. Hypertension 20,737–745 (1992).
   PubMed Web of Science ®Google Scholar
• Stoll M, Steckelings M, Paul M et al. The angiotensin AT2-receptor mediates inhibition of cell proliferation in coronary endothelial cells. J Clin. Invest. 95, 651–657 (1995).
   PubMed Web of Science ®Google Scholar
• Nakajima M, Hutchinson HG, Fujinaga M et al. The angiotensin II Type 2 (AT2) antagonizes the growth effect of the AT1 receptor. Proc. Natl Acad. Sci. USA 92, 10663–10667 (1995).
   PubMed Web of Science ®Google Scholar
• Velazquez EJ, Pfeffer MA. Acute heart failure complicating acute coronary syndromes. Circulation 109,440–442 (2004).
   PubMed Web of Science ®Google Scholar
• Pfeffer MA, Pfeffer JM, Lamas GA. Development and prevention of congestive heart failure following myocardial infarction. Circulation 87(5 Suppl.), IV120-1V125 (1993).
   Google Scholar
• Mitchell GF, Lamas GA, Pfeffer MA. Ventricular remodeling after myocardial infarction. Adv. EAR Med. Biol. 346, 265–276 (1993).
   PubMedGoogle Scholar
• •• Important paper on left ventricular dilation and prognosis in postmyocardial infarction (J\/II) patients.
   Google Scholar
• White HD, Norris MN, Brown MA et al. Left ventricular end-systolic volume as the major determinant of survival after recovery from myocardial infarction. Circulation 76(1), 44–51 (1987).
   PubMed Web of Science ®Google Scholar
• Pfeffer JM, Pfeffer MA, Fletcher PJ, Braunwald E. Progressive ventricular remodeling in rat with myocardial infarction. Am. J. PhysioL 260, H1406—H1414 (1991).
   Google Scholar
• Teerlink JR, Pfeffer JM, Pfeffer MA. Progressive ventricular remodeling in response to diffuse isoproterenol induced myocardial necrosis in rats. Circ. Res. 75(1), 105–113 (1994).
   PubMed Web of Science ®Google Scholar
• Fletcher PJ, Pfeffer JM, Pfeffer MA, Braunwald E. Left ventricular diastolic pressure—volume relations in rats with healed myocardial infarction. Effects on systolic function. Circ. Res. 49(3), 618–626 (1981).
   PubMed Web of Science ®Google Scholar
• Pfeffer MA, Pfeffer JM, Fishbein MC et al. Myocardial infarct size and ventricular function in rats. Circ. Res. 44(4), 503–512 (1979).
   PubMed Web of Science ®Google Scholar
• •• Important pioneer study on the effect of captopril in a post-MI animal model.
   Google Scholar
• Pfeffer JM, Pfeffer MA, Braunwald E. Hemodynamic benefits and prolonged survival with long-term captopril therapy in rats with myocardial infarction and heart failure. Circulation, 75,1149–1155 (1987).
   Web of Science ®Google Scholar
• Lamas GA, Pfeffer MA. Increased left ventricular volume following myocardial infarction in man. Am. Heart J. 111(1), 30–35 (1986).
   PubMed Web of Science ®Google Scholar
• Pfeffer MA, Lamas GA, Vaughan DE et al. Effect of captopril on progressive ventricular dilatation after anterior myocardial infarction. N Engl. J. Med. 319(2), 80–86 (1988).
   PubMed Web of Science ®Google Scholar
• Lamas GA, Pfeffer MA. Left ventricular remodeling after acute myocardial infarction: clinical course and beneficial effects of angiotensin-converting enzyme inhibition. Am. Heart J. 121,1194–1202 (1991).
   PubMed Web of Science ®Google Scholar
• Pfeffer MA, Braunwald E, Moye LA et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. The SAVE investigators. N Engl. J. Med. 327,669–677 (1992).
   PubMed Web of Science ®Google Scholar
• Sutton MS, Pfeffer MA, Plappert T et al. Quantitative two-dimentional echocardiographic measurements are major predictors of adverse cardiovascular events after acute myocardial infarction. Circulation 89,68–75 (1993).
   Web of Science ®Google Scholar
• The acute infarction ramipril efficacy (AIRE) study investigators: effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. Lancet342, 821–828 (1993).
   Google Scholar
• Kober L, Torp-Pedersen C, Carlsen JE et al. A clinical trial of the angiotensin-converting enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction. TRAndolapril Cardiac Evaluation (TRACE) Study Group. N Engl. J Med. 333 (25), 1670–1676 (1995).
   PubMed Web of Science ®Google Scholar
• ISIS-4 (Fourth International Study of Infarct Survival) Collaborative Group. ISIS-4: a randomized factorial trial assessing early oral captopril, oral mononitrate, and intravenous magnesium sulfate in 58,050 patients with suspected acute myocardial infarction. Lancet, 345, 669–685 (1995).
   PubMed Web of Science ®Google Scholar
• Gruppo Italian° per lo Studio della Sopravvivenza nell'infarto Miocardico. GISSI-3: effects of lisinopril and transdermal glyceryl trinitrate singly and together on 6-week mortality and ventricular function after acute myocardial infarction. Lancet, 343,1115–1122 (1994).
   PubMed Web of Science ®Google Scholar
• Zisman LS, Abraham WT, Meixell GE et al. Angiotensin II formation in the intact human heart: predominance of angiotensin-converting enzyme pathway. Clin. Invest. 96,1490–1496 (1995).
   Google Scholar
• Kokkonen JO, Saarinen J, Kovanen PT. Angiotensin II formation in human heart: an ACE or non-ACE-mediated pathway? Ann. Med. (Suppl. 1), 9–13 (1998).
   PubMed Web of Science ®Google Scholar
• •Great review for different angiotensin-converting enzyme (ACE) pathways in human heart.
   Google Scholar
• Urata H, Nishimura H, Ganten D. Mechanism of angiotensin II formation in humans. Euz: Heart J. 16(Suppl. N), 79–85 (1995).
   Google Scholar
• Wei CC, Meng QC, Palmer R et al. Evidence for angiotensin-converting enzyme and chymase-mediated angiotensin II formation in the interstitial fluid space of the dog heart in vivo. Circulation 99,2583–2589 (1999).
   PubMed Web of Science ®Google Scholar
• van den Meiracker AH, Man in't Veld AJ, Admiraal PJ et al. Partial escape of angiotensin-converting enzyme (ACE) inhibition during prolonged ACE inhibitor treatment: does it exist and does it affect the antihypertensive response? J. Hypertens. 8,803–812 (1992).
   Google Scholar
• •Important article explaining renin—angiotensin—aldosterone system escape.
   Google Scholar
• Pitt B. Escape of aldosterone production in patients with left ventricular dysfunction treated with an angiotensin converting enzyme inhibitor: implications for therapy. Cardiovasc. Drugs Ther 9,145–149 (1995).
   PubMed Web of Science ®Google Scholar
• Lakkis J, Lu WX, Weir MR. RAAS escape: a real clinical entity that may be important in the progression of cardiovascular and renal disease. CUIT: Hypertens. Rep. 5(5) 408–417 (2003).
   Google Scholar
• MacFadyen RJ, Lee AFC, Pringle SD et al. How often are angiotensin II and aldosterone concentration raised during chronic ACE inhibitor treatment in cardiac failure? Heart 82,57–61 (1999).
   PubMed Web of Science ®Google Scholar
• Lee AF, MacFadyen RJ, Struthers AD. Neurohormonal reactivation in heart failure Patients on chronic ACE inhibitor therapy: a longitudinal study. Eur I Heart Fail. 1(4), 401–406 (1999).
   Google Scholar
• Jorde UP, Vittoro T, Katz SD et al. Elevated plasma aldosterone levels despite complete inhibition of the vascular angiotensin-converting enzyme in chronic heart failure. Circulation 106,1055–1057 (2002).
   PubMed Web of Science ®Google Scholar
• Ciocoira M, Zanolla L, Franceschini L et al. Relationship of aldosterone escape despite angiotensin-converting enzyme inhibitor administration to impaired exercise capacity in chronic congestive heart failure secondary to ischemic or idiopathic dilated cardiomyopathy. Am. I CardioL 89(4), 403–407 (2002).
   PubMed Web of Science ®Google Scholar
• Roig E, Perez-Villa F, Morales M et al. Clinical implications of increased plasma angiotensin II despite ACE inhibitor therapy in patients with congestive heart failure. Eur Heart J. 21,53–57 (2000).
   PubMed Web of Science ®Google Scholar
• Califf RM, Cohn JN. Cardiac protection: evolving role of angiotensin receptor blockers. Am. Heart J. 139, S15—S22 (2000).
   Web of Science ®Google Scholar
• Peterson RC, Dunlap ME. Angiotensin II receptor blockers in the treatment of heart failure. Congest. Heart Fail. 8(5), 246–250 (2002).
   PubMedGoogle Scholar
• Schieffer B, Wirger A, Meybrunn et al., Comparative effects of chronic angiotensin-converting enzyme inhibition and angiotensin II Type 1 receptor blockade on cardiac remodeling after myocardial infarction in the rat. Circulation 89(5), 2273–2283 (1994).
   PubMed Web of Science ®Google Scholar
• ••Classic animal study of an angiotensinreceptor blocker (ARB) post MI.
   Google Scholar
• Jam M, Liao R, Ngoy S et al., Angiotensin II receptor blockade attenuates the deleterious effects of exercise training on post-MI ventricular remodeling in rats. Cardiovascular Res. 46,66–72 (2000).
   PubMed Web of Science ®Google Scholar
• •Nice review of different ARBs and their pharmacologic properties.
   Google Scholar
• Timmermans PB. Pharmacological properties of angiotensin II receptor antagonists. Can. J. CardioL 15\(Suppl. 9, F26—F28 (1999).
   PubMedGoogle Scholar
• Goa KL, Wagstaff AJ. Losartan potassium: a review of its pharmacology, clinical efficacy and tolerability in the management of hypertension. Drugs 51(5), 820–845 (1996).
   PubMed Web of Science ®Google Scholar
• Thurmann PA. Valsartan: a novel angiotensin Type 1 receptor antagonist. Expert Opin. Pharmacother.1 (2), 337–350 (2000).
   Google Scholar
• Adams MA, Trudeau L. Irbesartan: review of pharmacology and comparative properties. Can. J. Clin. PharmacoL 7(1), 22–31 (2000).
   PubMedGoogle Scholar
• Stoukides CA, McVay HJ, Kaul AF. Candesartan cilexetil: an angiotensin II receptor blacker. Ann. Pharmacother. 33(12) 1287–1298 (1999).
   PubMed Web of Science ®Google Scholar
• Burnier M, Maillard M. The comparative pharmacology of angiotensin II receptor antagonists. Blood Prem. 10 (Suppl. 1), 6–11 (2001).
   PubMedGoogle Scholar
• Hedner T. The clinical profile of the angiotensin II blacker eprosartan. Hypertens. 20 (Suppl. 5), 533—S38 (2003).
   Google Scholar
• Koike H, Sada T, Mizuno M. In vitro and in vivo pharmacology of olmesartan medoxamil, an angiotensin II type AT1 receptor antagonist. I Hypertens. 19\(Suppl. 1), S3—S14 (2001).
   Google Scholar
• Weber MA. Angiotensin II receptor blockers and cardiovascular outcomes: what does the future hold? J. Renin Angiotensin Aldosterone Syst. 4(2), 62–73 (2003).
   PubMed Web of Science ®Google Scholar
• McInnes GT, O'Kane KP, Istad H et al. Comparison of the AT1-receptor blacker, candesartan cilexetil, and the ACE inhibitor, lisinopril, in fixed combination with low dose hydrochlorothiazide in hypertensive patients. I Hum. Hypertens. 14(4), 263–269 (2000).
   PubMed Web of Science ®Google Scholar
• Pitt B, Segal R, Martinez FA et al. Randomized trial of losartan versus captopril in patients over 65 with heart failure (Evaluation of Losartan In The Elderly study [ELITE]). Lancet 349, 747–752 (1997).
   PubMed Web of Science ®Google Scholar
• Pitt B, Poole-Wilson PA, Segal R et al. Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomized trial — the losartan heart failure survival study ELITE II. Lancet 355,1582–1587 (2000).
   PubMed Web of Science ®Google Scholar
• Dickstein K, Kjekshus J. Comparison of the effects of losartan and captopril on mortality in patients after acute myocardial infarction: the OPTIMAAL trial design. OPtimal Therapy In Myocardial infarction with the Angiotensin II Antagonist Losartan. Am. CardioL 83(4), 477–481 (1999).
   PubMed Web of Science ®Google Scholar
• ••First large randomized trial of ARBcompared with ACE inhibitors in post-MI patients.
   Google Scholar
• Dickstein K, Kjekshus J, and the OPTIMAAL steering committee of the OPTIMAAL study group. Effects of Losartan and captopril on mortality and morbidity in high-risk patients after acute myocardial infarction: the OPTIMAAL randomized trial. Lancet 360,752–760 (2002).
   PubMed Web of Science ®Google Scholar
• Cohn JN, Tognoni G et al. A randomized trial of the angiotensin receptor blacker valsartan in chronic heart failure. N Engl. Med. 345,1667–1675 (2001).
   PubMed Web of Science ®Google Scholar
• Cohn JN. Lessons learned from the valsartan — heart failure trial (Val-HeFT): angiotensin receptor blockers in heart failure. Am.j CardioL 90(9), 992–993 (2002).
   PubMed Web of Science ®Google Scholar
• Carson P, Tognoni G, Cohn JN. Effect of valsartan on hospitalization: results from Val-HeFT. J. Card. Fail. (3), 164–171 (2003).
   PubMed Web of Science ®Google Scholar
• Swedberg K, Pfeffer M, Granger C et al. Candesartan in heart failure-assessment of reduction in mortality and morbidity (CHARM): rationale and design. Charm-Program Investigators. I Card. Fail. (3), 276–282 (1999).
   PubMed Web of Science ®Google Scholar
• Pfeffer MA, Swedberg K, Granger CB et al. Effects of candesartan on mortality an morbidity in patients with chronic heart failure: the CHARM-overall program. Lancet362, 759–766 (2003).
   Google Scholar
• ••Major trial for additional benefit ofcombination therapy of ACE inhibitor and ARB in patients with congestive heart failure.
   Google Scholar
• McMurray JJV, Ostergren J, Swedberg K et al. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-added trial. Lancet 362, 767–771 (2003).
   PubMed Web of Science ®Google Scholar
• Granger BG, McMurray JJV, Yusuf S et al. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-alternative trial. Lancet 362, 772–776 (2003).
   PubMed Web of Science ®Google Scholar
• Yusuf S, Pfeffer MA, Swedberg K et al. Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-preserved trial. Lancet 362,777–781 (2003).
   PubMed Web of Science ®Google Scholar
• Pfeffer MA, McMurray J, Leizorovicz A et al. Valsartan in acute myocardial infarction trial (VALIANT): rationale and design. Am. Heart J. 140(5), 727–750 (2000).
   PubMed Web of Science ®Google Scholar
• •• Major trial indicating equivalency of ARBs with ACE inhibitors in post-MI patients.
   Google Scholar
• Pfeffer MA, McMurray JJV, Velazquez EJ et al. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl. J. Med. 349, 1893–1906 (2003).
   PubMed Web of Science ®Google Scholar
• Mazzolai L, Maillard M, Rossat J et al. Angiotensin II receptor blockade in normotensive subjects. A direct comparison of three AT1 receptor antagonists. Hypertension 33,850–855 (1999).
   PubMed Web of Science ®Google Scholar
• Maillard MR Wurzner G, Nussberger J et al. Comparative angiotensin II receptor blockade in healthy volunteers: the importance of dosing. Clin. Pharmacol Ther. 71,68–76 (2002).
   PubMed Web of Science ®Google Scholar
• Mann DL, Deswal A. angiotensin receptor blockade in acute myocardial infarction: a matter of dose. N Engl. J. Med. 349,1963–1965 (2003).
   PubMed Web of Science ®Google Scholar
• Rouleau JL, de Champlain J, Klein M et al. Activation of neurohormonal systems in postinfarction left ventricular dysfunction. J. Am. Coll. Cardiol 22(2), 390–398 (1993).
   PubMed Web of Science ®Google Scholar
• Sigurdsson A, Swedberg K. Neurohormonal activation and congestive heart failure: todays experience with ACE inhibitors and rationale for their use. Eur Heart 16(Suppl. N), 65–72 (1995).
   PubMed Web of Science ®Google Scholar
• Vaughan DE, Lamas GA, Pfeffer MA. Role of left ventricular dysfunction in selective neurohormonal activation in the recovery phase of anterior wall acute myocardial infarction. Am. J Cardiol 66(5), 529–532 (1990).
   PubMed Web of Science ®Google Scholar
• Unger T The ongoing telmisartan alone and in combination with ramipril global end point trial program. Am. J Cardiol 91(10A), G28—G34 (2003).
   Google Scholar
• Pitt B, Remme W, Zannad F et al. Eplerenone, a selective aldosterone blacker, in patients with left ventricular dysfunction after myocardial infarction. N Engl. J Med. 348, 1309–1321 (2003).
   PubMed Web of Science ®Google Scholar
• Burnier M, Brunner HR. Angiotensin II receptor antagonists. Lancet 19,355 (9204), 637–645 (2000).
   Google Scholar